TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32379297

Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with MEK/ERK inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with WEE1/ATR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PARP inhibitors combined with PI3K/AKT/mTOR inhibitors
Number of subjects: 0
Study: 32379516

Group type: EXPERIMENTAL
Intervention: XR-NTX treatment
Number of subjects: 64
Study: 32379640

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weekly sessions)
Number of subjects: 39
Study: 32380357

Group type: EXPERIMENTAL
Intervention: Lymph Node Yield (LNY)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LNY per neck level
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: cN+ status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lymph Node Ratio (LNR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 100
Study: 32380442

Group type: EXPERIMENTAL
Intervention: dTMS protocol for OCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dTMS protocol for MDD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined dTMS protocols for OCD and MDD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (if applicable)
Number of subjects: 0
Study: 32380454

Group type: EXPERIMENTAL
Intervention: Opioid treatment
Number of subjects: 3441
Study: 32380535

Group type: EXPERIMENTAL
Intervention: sAML-like gene mutations (mutations in ASXL1, SRSF2, STAG2, BCOR, U2AF1, EZH2, SF3B1, ZRSR2)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Routine analysis of sAML-like gene mutations
Number of subjects: 509
Study: 32380537

Group type: EXPERIMENTAL
Intervention: Varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Varlilumab (0.3 mg/kg every 3 weeks, 4 doses per cycle, up to 5 cycles) in an expansion cohort of 4 patients with Hodgkin lymphoma
Number of subjects: 30
Study: 32380536

Group type: EXPERIMENTAL
Intervention: Dose-dense immunochemotherapy with early systemic CNS prophylaxis (2 courses of high-dose methotrexate, biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOEP and 1 course of high-dose cytarabine with R, plus intrathecal liposomal cytarabine at courses 1, 3, and 5)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Previous trial with systemic CNS prophylaxis given after 6 courses of biweekly R-CHOEP
Number of subjects: 139
Study: 32380538

Group type: EXPERIMENTAL
Intervention: Ivosidenib (targeted mutant IDH1 enzyme inhibitor)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 174
Study: 32380978

Group type: EXPERIMENTAL
Intervention: Pharmacist-provided HIV point-of-care testing (POCT) program
Number of subjects: 123
Study: 32381080

Group type: EXPERIMENTAL
Intervention: Anti-mycobacterial treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 114
Study: 32381098

Group type: EXPERIMENTAL
Intervention: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen (isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months, followed by isoniazid, rifampicin, ethambutol for 6 months)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo with standard anti-TB regimen
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen
Number of subjects: 181
Study: 32381107

Group type: EXPERIMENTAL
Intervention: Abdominal infections
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Pulmonary infections
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Skin/Soft Tissue infections
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Genitourinary infections
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Vascular infections
Number of subjects: 316
Study: 32381452

Group type: EXPERIMENTAL
Intervention: 3-component or 2-component prosthesis with subtalar arthrodesis
Number of subjects: 23
Study: 32381495

Group type: EXPERIMENTAL
Intervention: Video-observed therapy (VOT)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Clinic-based directly observed therapy (DOT)
Number of subjects: 197
Study: 32381630

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg orally per day for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo orally per day for 12 months
Number of subjects: 60
Study: 32382685

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 1602
Study: 32382714

Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine (2 doses IM 56 days apart)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (2 doses IM 56 days apart)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BCG revaccination (single dose ID)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 84
Study: 32382720

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Standard 10 Hz rTMS
Number of subjects: 388
Study: 32382759

Group type: EXPERIMENTAL
Intervention: African American adults
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-Hispanic White adults
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 32382869

Group type: EXPERIMENTAL
Intervention: Angiogenesis imaging with tracers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tracers used for imaging
Number of subjects: 10
Study: 32383099

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative approaches (e.g., prevalence function, Q-TWiST, ToxT, recurrent event approaches)
Number of subjects: 0
Study: 32383192

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (first-line treatment)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine, or ibrutinib (second-line treatment)
Number of subjects: 139
Study: 32383296

Group type: EXPERIMENTAL
Intervention: Temporally Feathered Radiation Therapy (TFRT)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Non-TFRT IMRT plan
Number of subjects: 1
Study: 32383391

Group type: EXPERIMENTAL
Intervention: RF/PF (40 patients)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PF/PF (36 patients)
Number of subjects: 76
Study: 32383679

Group type: EXPERIMENTAL
Intervention: Tailored complex intervention including a dialogue tool and a workshop on UTI for nursing home staff
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1274
Study: 32383840

Group type: EXPERIMENTAL
Intervention: Beta-peripapillary atrophy (B-PPA) present in eyes developing GA
Number of subjects: 490

Group type: COMPARATOR
Intervention: Beta-peripapillary atrophy (B-PPA) absent in eyes without GA
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Greater circumferential extent of sclera/choroidal blood vessels B-PPA
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Beta-peripapillary atrophy (B-PPA)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Patients without B-PPA
Number of subjects: 490
Study: 32384051

Group type: EXPERIMENTAL
Intervention: Internet Attachment-Based Compassion Therapy (iABCT)
Number of subjects: 35
Study: 32384343

Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 133
Study: 32384433

Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 32384454

Group type: EXPERIMENTAL
Intervention: Integrated care model (Salut+Social) with improved coordination between social and healthcare sectors using ICT tools for 6 months
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Caregiver experience evaluation
Number of subjects: 141
Study: 32384876

Group type: EXPERIMENTAL
Intervention: Flutemetamol PET imaging
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cortical amyloid deposition
Number of subjects: 208
Study: 32384884

Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment for 8 weeks
Number of subjects: 78
Study: 32385062

Group type: EXPERIMENTAL
Intervention: Exposure to environmental chemicals (perfluoroalkyl substances, phenols, phthalates, flame retardants)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Exposure to environmental chemicals
Number of subjects: 441
Study: 32385089

Group type: EXPERIMENTAL
Intervention: Direct transport to ECCs
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Direct transport to iECC (within 20 miles)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Direct transport to iECC (≤20 miles)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Direct transport to ECCs (≤20 miles)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Bypass to iECC modeling under 20 miles
Number of subjects: 236
Study: 32385144

Group type: EXPERIMENTAL
Intervention: Immunotherapic vaccine comprising phosphorylated BCAR3 peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapic vaccine comprising phosphorylated IRS2 peptide
Number of subjects: 0
Study: 32385529

Group type: EXPERIMENTAL
Intervention: Noncalcified plaque burden
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Low-density plaque burden
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Visually identified plaque in SB segment
Number of subjects: 340
Study: 32385580

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs) initiating weight management conversations
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Perception of obesity as a chronic disease
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Responsibility for weight loss
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Time before discussing weight with HCP
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: HCPs' perception of patient motivation
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Appointment time limitations
Number of subjects: 1501
Study: 32385603

Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous glucose infusions (IGIVI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral glucose administration
Number of subjects: 23
Study: 32385604

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 3576

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 3576

Group type: COMPARATOR
Intervention: Any fatty acid
Number of subjects: 3576
Study: 32385645

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32385714

Group type: EXPERIMENTAL
Intervention: CDK7 inhibitors (CDK7i)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CDK7i with other targeted cancer therapies (BET inhibitors, BCL2 inhibitors, hormone therapies)
Number of subjects: 0
Study: 32385774

Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (PVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiofrequency cavo-tricuspid isthmus (CTI) ablation
Number of subjects: 0
Study: 32385824

Group type: EXPERIMENTAL
Intervention: Manual lateral displacement of the skin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30° external rotation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Straight leg raised to 30°
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Knee and hip flexed to 90°
Number of subjects: 40
Study: 32385845

Group type: EXPERIMENTAL
Intervention: 0.2% sirolimus gel applied twice daily for > 52 weeks (maximum 136 weeks)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 0.2% sirolimus gel
Number of subjects: 94
Study: 32386106

Group type: EXPERIMENTAL
Intervention: Pharmacy records adherence
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume (MCV) adherence
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fetal hemoglobin (HbF) adherence
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Urine assay adherence
Number of subjects: 34

Group type: COMPARATOR
Intervention: Video directly observed therapy (VDOT) adherence
Number of subjects: 34
Study: 32386199

Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve (BAV)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Tricuspid aortic valve (TAV)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: BAV
Number of subjects: 141

Group type: COMPARATOR
Intervention: TAV
Number of subjects: 141
Study: 32386226

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 171
Study: 32386512

Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Obese (MHO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metabolically Unhealthy Obese (MUO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Weight (NW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive metabolic profiling
Number of subjects: 0
Study: 32386566

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study: 32386568

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) plus carboplatin and nab-paclitaxel (100 mg/m²) as neoadjuvant treatment.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and nab-paclitaxel.
Number of subjects: 30
Study: 32386745

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Parental report of severe side-effects three days after vaccination
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Worry about side-effects one month after vaccination
Number of subjects: 270
Study: 32386744

Group type: EXPERIMENTAL
Intervention: Antimalarial drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32387010

Group type: EXPERIMENTAL
Intervention: HIVAX therapeutic HIV vaccine
Number of subjects: 0
Study: 32387378

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 100
Study: 32387522

Group type: EXPERIMENTAL
Intervention: Level 3 portable sleep study
Number of subjects: 263

Group type: COMPARATOR
Intervention: Level 1 polysomnography
Number of subjects: 263
Study: 32387546

Group type: EXPERIMENTAL
Intervention: Manually Initiated workflow
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clarity proprietary software
Number of subjects: 32
Study: 32387572

Group type: EXPERIMENTAL
Intervention: Patients with midline incisional hernia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (patients without hernia)
Number of subjects: 36
Study: 32387696

Group type: EXPERIMENTAL
Intervention: Streamlined basophil activation test (BAT) using a dry and room temperature stable reagent technology, 15 min incubation at 37 °C, 4 pipetting steps, and analyzed by flow cytometry.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New BAT procedure transposed into a 96 well plate format.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characterization of ex vivo basophil reactivity using 8 dilution points with 5 μL of blood per point.
Number of subjects: 0
Study: 32388060

Group type: EXPERIMENTAL
Intervention: Registry data collection from 232 MG patients
Number of subjects: 232
Study: 32388653

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15
Study: 32389183

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) and glecaprevir-pibrentasvir (300 mg/120 mg) given one dose 6-12 hours before transplant and once a day for 7 days after surgery (total of 8 doses)
Number of subjects: 30
Study: 32389229

Group type: EXPERIMENTAL
Intervention: Qualitative interviews and smartphone/tablet app reporting
Number of subjects: 27
Study: 32390114

Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size < 10%
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size ≥ 10%-< 50%
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocyte clone size ≥ 50%
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 4439
Study: 32390133

Group type: EXPERIMENTAL
Intervention: Oral protein-based nutritional supplements
Number of subjects: 1278
Study: 32390227

Group type: EXPERIMENTAL
Intervention: LENT score
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: modified-LENT score
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PROMISE score
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: SELECT model
Number of subjects: 130
Study: 32390277

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days in a 28-day cycle)
Number of subjects: 30
Study: 32390533

Group type: EXPERIMENTAL
Intervention: Pacemaker-mediated QRS widening with gradual desynchronization of LV contraction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Wide QRS rhythm ensured by dual pacing, dual sensing, and dual response to sensing with short AVD
Number of subjects: 34
Study: 32390569

Group type: EXPERIMENTAL
Intervention: Patients with PAD (N=25)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patients without PAD (N=7)
Number of subjects: 25
Study: 32390591

Group type: EXPERIMENTAL
Intervention: Am Mindfulness-Based Cancer Survivorship-MBCS-Journey (app-based mindfulness intervention)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 83
Study: 32390862

Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy (ICM) with VT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy (ICM) no VT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 32391157

Group type: EXPERIMENTAL
Intervention: MDW > 20.0
Number of subjects: 2158

Group type: COMPARATOR
Intervention: MDW ≤ 20.0
Number of subjects: 2158
Study: 32391374

Group type: EXPERIMENTAL
Intervention: Acute reduction in dietary protein intake (5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual protein intake (control group)
Number of subjects: 0
Study: 32391524

Group type: EXPERIMENTAL
Intervention: COAST-IS intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Learning collaborative only (control)
Number of subjects: 0
Study: 32392298

Group type: EXPERIMENTAL
Intervention: Residual glucocorticoid (GC) production
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Residual mineralocorticoid (MC) production
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Peak cortisol response
Number of subjects: 192
Study: 32392316

Group type: COMPARATOR
Intervention: Patients without diabetic retinopathy (no-DR)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Patients with increasing severity of diabetic retinopathy (mild, moderate/severe, proliferative)
Number of subjects: 192
Study: 32392512

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids (prednisolone-equivalent dose)
Number of subjects: 71642

Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid prednisolone-equivalent dose
Number of subjects: 71642
Study: 32392558

Group type: EXPERIMENTAL
Intervention: NETest (multigene assay comprising 51 circulating NET-specific transcripts)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: NETest integrated with epigenome/metastasome levels
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: High NETest (>40) including fibrosome/NEDome
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Integration of four omes (epigenome, metastasome, fibrosome, NEDome) with NETest score
Number of subjects: 222

Group type: COMPARATOR
Intervention: Twelve omes excluding inflammasome and apoptome
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Seven omes (proliferome, NEDome, epigenome, SSTRome, neurome, metastasome, fibrosome)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Seven omes
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Septet omic expression
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Integration of quartet (epigenome, fibrosome, metastasome, NEDome) and NETest score
Number of subjects: 222
Study: 32393184

Group type: EXPERIMENTAL
Intervention: Group 3: PCP counseling/encouragement, in-office tele-HS, and educational materials
Number of subjects: 660

Group type: COMPARATOR
Intervention: Group 2: PCP counseling/encouragement on importance of hearing screening, instructions to take the tele-HS from home, educational materials
Number of subjects: 660

Group type: COMPARATOR
Intervention: Group 1: Instructions for tele-HS to complete at home and educational materials on warning signs and consequences of hearing loss
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: All groups (fail tele-HS)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 660
Study: 32393207

Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase levels
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cobb angles, spinal bone mass densities
Number of subjects: 67
Study: 32393288

Group type: EXPERIMENTAL
Intervention: Adaptive mapping that was iteratively updated by recalculating the principal components based on ongoing movements.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixed mapping throughout the experiment.
Number of subjects: 20
Study: 32393328

Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 91
Study: 32393334

Group type: EXPERIMENTAL
Intervention: Nurse home-visiting program
Number of subjects: 739
Study: 32393350

Group type: COMPARATOR
Intervention: ASD group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Over-responsive subgroup (n = 35)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Under-responsive subgroup (n = 89)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Under-responsive group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Over-responsive subgroup
Number of subjects: 165